VBL Therapeutics is an innovative and diversified, clinical stage biotechnology company
VBL Therapeutics is an innovative and diversified, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases. Currently available therapies are limited in their ability to adequately treat these serious and oftentimes life-threatening diseases. VBL was founded to create new treatment options that address these unmet medical needs.VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 20, 2021 | Grant | €2.50M | 1 | European Innovation Council | — | Detail |
Dec 20, 2021 | Post-IPO Equity | €15M | 1 | European Innovation Council | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Innovation Council | Yes | Grant |